Sichenzia Ross Ference LLP Represents H.C. Wainwright in $40.0 Million Registered Direct Offering of Pulmatrix, Inc.
Press Release – New York, NY – February 17, 2020 – Sichenzia Ross Ference LLP announced today that it represented H.C. Wainwright & Co., LLC as exclusive placement agent in a $40.0 million public offering of the common stock of Pulmatrix, Inc. (NASDAQ: “PULM”), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The registered direct offering with certain healthcare-focused institutional investors consisted of the sale 20,000,000 shares of common stock, for aggregate gross proceeds of approximately $40.0 million.
The shares of common stock were offered by Pulmatrix pursuant to a “shelf” registration statement on Form S-3 (File No. 333-230225) previously filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2019 and declared effective by the SEC on March 15, 2019.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Arthur Marcus, Darrin M. Ocasio and law clerk Zachary Weiss.